The measurement of antibodies binding to IFNbeta in MS patients treated with IFNbeta. by Pachner, A, Oger, J, Palace, J

The measurement of antibodies binding to IFNbeta in MS patients treated with IFNbeta. by Pachner, A, Oger, J, Palace, J

The measurement of antibodies binding to IFNβ in MS patients treated with IFNβ by Pachner, A, Oger, J, Palace, J

A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFN beta. by Lawrence, N, Oger, J, Aziz, T, Palace, J, Vincent, A

Potassium channel antibodies in two patients with reversible limbic encephalitis. by Buckley, C, Oger, J, Clover, L, Tüzün, E, Carpenter, K, Jackson, M, Vincent, A

Improving the model for the uk ms disease modifying treatment risk sharing scheme analysis: a new natural history dataset. by Palace, J, Bregenzer, T, Tremlett, H, Duddy, M, Boggild, M, Zhu, F, Oger, J, Dobson, C

Modelling natural history for the UK multiple sclerosis risk-sharing scheme by Palace, J, Bregenzer, T, Tremlett, H, Duddy, M, Boggild, M, Zhu, F, Oger, J, Dobson, C

UK multiple sclerosis risksharing scheme: A new natural history dataset and an improved Markov model by Palace, J, Bregenzer, T, Tremlett, H, Oger, J, Zhu, F, Boggild, M, Duddy, M, Dobson, C

UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. by Palace, J, Bregenzer, T, Tremlett, H, Oger, J, Zhu, F, Zhu, F, Boggild, M, Duddy, M, Dobson, C

CAUSE OF DEATH IN MULTIPLE SCLEROSIS PATIENTS FROM THE 21-YEAR LONG-TERM FOLLOW-UP STUDY by Ebers, G, Cook, S, Cutter, G, Goodin, D, Reder, A, Kremenchutzky, M, Oger, J, Rametta, M, Beckmann, K, Bogumil, T, Knappertz, V

Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study by Goodin, D, Ebers, G, Cutter, G, Cook, S, O'Donnell, T, Reder, A, Kremenchutzky, M, Oger, J, Rametta, M, Beckmann, K, Knappertz, V

Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. by Goodin, D, Reder, A, Ebers, G, Cutter, G, Kremenchutzky, M, Oger, J, Langdon, D, Rametta, M, Beckmann, K, DeSimone, T, Knappertz, V

A GENETIC-BASIS FOR FAMILIAL AGGREGATION IN MULTIPLE-SCLEROSIS by Ebers, G, Sadovnick, A, Risch, N, Bulman, D, Rice, G, Hashimoto, S, Paty, D, Oger, J, Metz, L, Bell, R, Warren, S, Hader, W, Auty, T, Nath, A, Gray, T, Oconnor, P, Nelson, R, Freedman, M, Brunet, D, Paulseth, R, Francis, G, Duquette, P, Murray, T, Bahn, V, Prysephillips, W

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1... by Ebers, G, Rice, G, Lesaux, J, Paty, D, Oger, J, Li, D, Beall, S, Devonshire, V, Hashimoto, S, Hooge, J, Kastrukoff, L, Krieger, C, Mezei, M, Seland, P, Vorobeychi, G, Morrison, W, Nelson, J, Freedman, MS, Chrisie, S, Nelson, R, Rabinovitch, H, Freedman, C, Hartung, H, Rieckmann, P, Archelos, J

Evidence for genetic basis of multiple sclerosis by Sadovnick, A, Ebers, G, Dyment, D, Risch, N, Bulman, D, Rice, G, Hashimoto, SA, Paty, D, Oger, J, Metz, L, Bell, R, Warren, S, Hader, W, Auty, T, Nath, A, Gray, T, OConner, P, Nelson, R, Freedman, M, Brunet, D, Paulseth, R, Francis, G, Duquette, P, Murray, T, Bahn, V

INTERFERON BETA-1B IN THE TREATMENT OF MULTIPLE-SCLEROSIS - FINAL OUTCOME OF THE RANDOMIZED CONTROLLED TRIAL by Duquette, P, Despault, L, Knobler, R, Lublin, F, Kelley, L, Francis, G, Freedman, M, Lapierre, Y, Greenstein, J, Mishra, B, Delillio, N, Whitaker, J, Layton, B, Sibley, W, Laguna, J, Krikawa, J, Paty, D, Oger, J, Kastrukoff, L, Morrison, W, Nelson, J, Goodin, D, Massa, S, Gutteridge, E, Arnason, B

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS by Francis, G, Hughes, R, King, J, Mitchell, P, Joubert, J, McLeod, J, Parker, G, Pollard, J, Sindic, C, Duprez, T, Medaer, R, Broeckx, J, Vanroose, E, Carton, H, Wilms, G, Rice, G, Ebers, G, Lee, D, Freedman, M, Nelson, R, Rabinovitch, H, Christie, S, Avruch, L, Oger, J, Paty, D

A full genome search in multiple sclerosis. by Ebers, G, Kukay, K, Bulman, D, Sadovnick, A, Rice, G, Anderson, C, Armstrong, H, Cousin, K, Bell, R, Hader, W, Paty, D, Hashimoto, S, Oger, J, Duquette, P, Warren, S, Gray, T, O'Connor, P, Nath, A, Auty, A, Metz, L, Francis, G, Paulseth, J, Murray, T, Pryse-Phillips, W, Nelson, R

Genetic susceptibility to MS: a second stage analysis in Canadian MS families. by Dyment, D, Willer, C, Scott, B, Armstrong, H, Ligers, A, Hillert, J, Paty, D, Hashimoto, S, Devonshire, V, Hooge, J, Kastrukoff, L, Oger, J, Metz, L, Warren, S, Hader, W, Power, C, Auty, A, Nath, A, Nelson, R, Freedman, M, Brunet, D, Paulseth, J, Rice, G, O'Connor, P, Duquette, P

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years by Duquette, P, Girard, M, Dubois, R, Kobler, R, Lublin, F, Kelley, L, Francis, G, Freedman, M, Greenstein, J, Mishra, B, DeLillio, N, Whitaker, J, Layton, B, Sibley, W, Laguna, J, Krikawa, J, Paty, D, Oger, J, Kastrukoff, L, Morrison, W, Nelson, J, Goodin, D, Massa, S, Gutteridge, E, Arnason, B